We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2082:TADAWULACWA Power Company Analysis

Data as of 2026-03-14 - not real-time

SAR 167.60

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ACWA Power is trading at 167.6 SAR, well below its 20‑day (170.6) and 50‑day (176.6) moving averages, signaling a bearish technical backdrop. The RSI sits at 43.8, indicating modest momentum, while the MACD histogram turned positive, offering a faint bullish hint. Valuation metrics are stretched: a trailing PE of 68 versus an industry average of 23 and a DCF fair value of only 84 SAR suggest the stock is overvalued. Fundamentals show solid revenue growth of 17.5% and healthy margins, yet the company carries a high debt load (debt‑to‑equity >100%) and negative free cash flow, raising financial risk. Analyst consensus is a sell with median target 134.5 SAR, well under the current price.
Given the elevated volatility (33% 30‑day) but low market beta (0.17), price swings are likely driven by company‑specific factors rather than broad market moves. The absence of dividends and the heavy leverage further dampen the investment case, while the strategic shift toward renewables and green hydrogen offers long‑term upside if execution improves.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below 20‑day and 50‑day SMAs
  • High trailing PE relative to peers
  • Negative free cash flow and high leverage

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and improving forward EPS
  • Forward PE still elevated but lower than trailing
  • Ongoing regulatory transition toward renewables

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strategic diversification into green hydrogen and renewables
  • Long‑term power purchase agreements providing stable cash flows
  • Persistent high debt levels and valuation gap

Key Metrics & Analysis

Financial Health

Revenue Growth17.50%
Profit Margin24.98%
P/E Ratio68.1
ROE7.36%
ROA2.55%
Debt/Equity100.68
P/B Ratio4.4
Op. Cash FlowSAR4.5B
Free Cash FlowSAR-2917199872
Industry P/E23.3

Technical Analysis

TrendBearish
RSI43.8
SupportSAR 149.40
ResistanceSAR 184.40
MA 20SAR 170.64
MA 50SAR 176.57
MA 200SAR 209.60
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueSAR 83.77
Target PriceSAR 154.00
Upside/Downside-8.11%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.17
Volatility33.20%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.